December 12, 2016 / 12:34 PM / 8 months ago

BRIEF-Achaogen says positive results in phase 3 trials of plazomicin

1 Min Read

Dec 12 (Reuters) - Achaogen Inc

* Plazomicin well tolerated in both trials and shows improved overall safety compared with colistin in care trial

* Company plans to proceed with regulatory submissions in U.S. and Europe

* Epic registration trial successfully achieves FDA primary endpoints in patients with complicated urinary tract infections

* In addition, achaogen plans to publicly present detailed results from both Epic and Care trials in 2017

* Company also plans to submit a marketing authorization application (MAA) to EMA in 2018

* Epic demonstrates superiority on EMA primary endpoints

* Company plans to proceed with regulatory submissions in U.S. And europe

* Achaogen plans to submit a new drug application (NDA), which will include Epic and Care data, to FDA in second half of 2017

* Achaogen announces positive results in phase 3 CUTI and CRE clinical trials of plazomicin Source text for Eikon: Further company coverage: (

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below